HeerspinkHJL, et al.Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet2023; 401:1584–1594. doi: 10.1016/S0140-6736(23)00569-X
HeerspinkHJL, Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023; 401:1584–1594. doi: 10.1016/S0140-6736(23)00569-X)| false